IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3A9mZOc
via IFTTT